ACE Research Supports Launch of a New Mpox Vaccine Clinical Trials in Pregnant Women, Breastfeeding Mothers, and Infants in the DRC
KISUMU, Kenya, July 1, 2025
ACE Research is proud to announce its role as Clinical Research Organization (CRO) in new scientific clinical trials evaluating the MVA-BN® mpox vaccine, developed by Bavarian Nordic, in populations at highest risk of severe outcomes – pregnant women, breastfeeding mothers, and infants.
These research studies are being conducted in the Democratic Republic of Congo (DRC), currently the epicenter of the ongoing mpox outbreak. The trials are part of the broader PregInPoxVac project and aim to generate critical data on the safety and immunogenicity of the MVA-BN® vaccine in vulnerable populations historically underrepresented in vaccine research.
The initiative includes two Phase 3 clinical trials:
NCT06844487: Evaluating infant safety and immunogenicity
NCT06844500: Evaluating maternal safety and immunogenicity in pregnant and breastfeeding women
“We are deeply committed to advancing clinical research that addresses urgent global health challenges,” said Ms. Victorine Owira, CEO, ACE Research.
Dr. Amos Ndhere, Chief Medical Officer said “These new studies will help us better understand how the MVA-BN vaccine works in pregnant women and infants — groups who need protection the most. We’re proud to support our partners in making this research possible and helping bring the vaccine to those who need it most.”
ACE Research is honored to collaborate with esteemed partners on this project, including the University of Antwerp, the University of Kinshasa, and the Penta Foundation – Child Health Research.
This important work is made possible through the support of our funders: CEPI (Coalition for Epidemic Preparedness Innovations), Global Health EDCTP3, and Bavarian Nordic.
About ACE Research
ACE Research is a trusted African CRO, providing end-to-end support for clinical trials with a focus on infectious diseases, emerging and re-emerging pathogens, and public health emergencies. ACE is committed to high-quality, ethical research that drives global health equity.
For media inquiries or more information, please contact:
Oliver Kipkemei
Corporate Communications Office
Email: office@aceresearchafrica.com
Tel: +254(0)796145263
Website: https://aceresearchafrica.com/